Adapalene: The Over the Counter Retinoid Explained

What Adapalene Is

Adapalene is a synthetic retinoid built from naphthoic acid. It is not vitamin A and it is not a version of vitamin A that your skin has to convert. Review articles class it as a third generation retinoid alongside tazarotene, with tretinoin, which is all-trans-retinoic acid itself, as the first generation compound the newer ones were designed to improve on (Bikowski, J Drugs Dermatol 2005, PMID 15696984).

Three properties get repeated across the pharmacology reviews, and they explain most of what follows. Adapalene has selective affinity for the nuclear retinoic acid receptors and does not bind the cytosolic retinoic acid binding proteins. It is highly lipophilic. And it has greater chemical and photostability than tretinoin (Jain, J Dermatolog Treat 2004, PMID 15764031). A separate review notes that only trace amounts of adapalene are absorbed after topical application, and offers that as a possible explanation for its relatively low irritancy rather than a demonstrated one (Bershad, Semin Cutan Med Surg 2001, PMID 11594670).

What Over The Counter Actually Means Here

This is the part most monographs get loose about, so here is the checkable version. On 8 August 2026 we queried Drugs@FDA, the US Food and Drug Administration approvals database, filtering on the product active ingredient name field. Adapalene returned 31 application records. Counting the individual products inside those records rather than the applications, 10 carry an over the counter marketing status, 21 carry prescription, and 4 are discontinued.

Running the same field filter on the other retinoids: tretinoin, once its oral capsule products are excluded by dosage form, returned 43 prescription and 12 discontinued topical products on that same product count, and no over the counter ones. Tazarotene returned 20 prescription and 2 discontinued products, and trifarotene a single prescription product, with no over the counter status in either. Retinol returned nothing at all, because retinol reaches the shelf as a cosmetic ingredient rather than as an approved drug product, which is why it is not regulated on this axis in the first place.

Inside the US database the split is not by molecule, it is by product. Adapalene 0.1% gel under NDA 020380 is over the counter. Adapalene 0.1% cream under NDA 020748 is prescription. Same active, same strength, different vehicle, different status. The 0.3% gel under NDA 021753, approved 19 June 2007, is prescription.

The fourth row is new enough that most pages on this topic have not caught it. The adapalene plus benzoyl peroxide fixed combination was approved on 22 May 2026 under application NDA 220736, filed under the submission class the FDA labels a partial prescription to over the counter switch. The originator brand at that same 0.1% and 2.5% strength, NDA 022320, now shows as discontinued, although generic prescription products at those strengths are still listed, and the higher strength 0.3% combination remains prescription. When the FDA published its OTC decision for the single ingredient 0.1% gel in 2016, a later analysis of sales and prescriber data reported that the switch increased access and lowered costs to patients and payers, including Medicare patients, in the US (Fix et al., Arch Dermatol Res 2024, PMID 38734769).

Adapalene vs Tretinoin vs Retinol

The comparison the monographs skip. These three are not three strengths of one thing. They are three different molecules with different regulatory lives.

On efficacy, the honest answer is that it depends which tretinoin you mean, and the literature says both things. A 2004 review of the comparative trials concluded that tretinoin 0.05% gel showed greater anti-acne efficacy than adapalene 0.1% gel, but that it also carried higher skin irritation potential (Jain, PMID 15764031). Against the weaker tretinoin gel 0.025%, a review of three pivotal controlled studies involving almost 900 patients in total across all treatment arms reported adapalene 0.1% gel and solution as at least as effective, with superior local tolerability and a significantly more rapid onset of clinical effect (Millikan, PMID 11843229).

Both statements can be true because they compare different concentrations. Anyone weighing two products is comparing two specific percentages, not two molecule names. For the retinol side of this comparison, our tretinoin vs retinol guide and the retinoid vs retinol explainer cover the conversion question in more depth.

What The Registration Trial Actually Measured

The FDA approved labelling for adapalene gel 0.3% carries the results of a 12 week, multi-center, controlled trial in 653 patients aged 12 to 52 with mild to moderate acne vulgaris. It ran three arms: adapalene 0.3% gel in 258 patients, adapalene 0.1% gel in 261, and vehicle gel in 134. Success was defined as Clear or Almost Clear on the Investigator Global Assessment.

Two things in that table are worth sitting with. First, the vehicle gel, which is the formulation with no adapalene in it, still produced a 33.7% mean reduction in total lesions. The gap that belongs to the drug in the over the counter strength is 41.8% against 33.7%, roughly 8 percentage points on lesion count, and 16% against 9% on the stricter Clear or Almost Clear measure. Second, tripling the concentration from 0.1% to 0.3% moved total lesion reduction from 41.8% to 45.3% and IGA success from 16% to 21%. Real, but smaller than the jump in prescription status suggests. Neither of these is a reason to use or avoid anything, and the trial reports group averages, not what happens to any individual.

Zooming out, a 2023 network meta-analysis of 221 randomised controlled trials covering 37 interventions, with 65,601 patients in its primary total lesion analysis and a mean age of 20.4 years, ranked oral isotretinoin as the most effective acne treatment overall, followed by triple therapy combining a topical antibiotic, a topical retinoid and benzoyl peroxide, then a triple therapy using an oral antibiotic instead. For monotherapies, it reported that oral or topical antibiotics and topical retinoids have comparable efficacy for inflammatory lesions, while the antibiotics have less effect on non-inflammatory lesions (Huang et al., Ann Fam Med 2023, PMID 37487721).

A separate network meta-analysis restricted to mild to moderate acne, covering 35 randomised trials and 33,472 participants aged 12 and over with at least 12 weeks of topical treatment, put adapalene with benzoyl peroxide among the three combinations with the greatest total lesion reduction against placebo. Its other finding matters just as much: there was no significant difference among most single agents on lesion count reduction. Its literature searches were run on 29 November 2021, so trials after that date are not in it (Kakpovbia et al., J Eur Acad Dermatol Venereol 2025, PMID 38943431). A 2020 Cochrane review of topical benzoyl peroxide reached a compatible conclusion from the other direction, finding that there may be little to no difference between benzoyl peroxide and adapalene on participant reported acne improvement, with a risk ratio of 0.99 and a 95% confidence interval of 0.90 to 1.10 drawn from 5 trials and 1,472 participants across both arms, graded low certainty (Yang et al., Cochrane Database Syst Rev 2020, PMID 32175593).

The Gentler Reputation, Tested

Adapalene is described everywhere as the gentle retinoid. The comparative reviews do support that relative to tretinoin, and the labels also show that gentle does not mean uneventful. In the same 12 week trial, local cutaneous irritation was monitored in 258 acne subjects using the 0.3% gel once daily. The label reports the incidence of scores higher than baseline, split by maximum severity, in the 253 subjects with at least one post-baseline evaluation.

Those three columns are separate categories and should stay separate. Mild dryness in 44.7% of subjects is not the same event as severe dryness in 0.8%. The label summarises the pattern as: among subjects who experienced cutaneous irritation, the majority of cases were mild to moderate in severity, occurred early in treatment, and decreased thereafter. The warnings section adds that these signs were most likely during the first four weeks, mostly mild to moderate in intensity, and usually lessened with continued use. The label also records the reverse direction, listing acne flare, contact dermatitis, eyelid oedema, conjunctivitis, pruritus, skin discoloration, rash and eczema each in under 1% of subjects, and a one year open-label safety trial in 551 subjects where the pattern of adverse reactions was similar to the 12 week study.

The early worsening line is the one most often quoted in half. The label pairs it with a condition: continue as directed unless irritation becomes severe, and severe irritation appears separately on the stop use and ask a doctor list. Our retinoid purge guide goes into how the adjustment period is distinguished from plain irritation.

Evidence In Asian Skin

Worth knowing before you take the numbers above as yours. The trial behind the approved US efficacy figures reported its enrolment as 72% Caucasian, 12% Hispanic, 10% African-American, 3% Asian and 2% other. That is 3% Asian participation in the study that produced the 41.8% and 16% figures. It is not a reason to distrust them, but it is a reason not to treat them as measured in a Vietnamese population.

There is better matched evidence. A trial at three dermatology clinics in China randomised 150 patients with grade II to III acne vulgaris to 8 weeks of once daily adapalene gel 0.1% or tretinoin gel 0.025%, with 139 completing the efficacy evaluation and 144 the safety evaluation. Both arms produced reductions in total, inflammatory and non-inflammatory lesion counts in the range of 69 to 74% on average, and more than 70% of patients in both groups had complete clearance or marked improvement. Irritation was in general mild, but it was both more common and more severe in the tretinoin group than the adapalene group. The authors noted that Asian skin types tend toward post-inflammatory hyperpigmentation, which is part of why the tolerability difference matters beyond comfort (Tu et al., J Eur Acad Dermatol Venereol 2001, PMID 11843231).

Two smaller studies looked specifically at whether a moisturiser changes how adapalene feels. A 4 week randomised, investigator-blinded, split-face study in 30 healthy volunteers of Chinese origin applied adapalene gel to the whole face and a moisturising lotion to one side only. Both investigators and subjects reported better tolerance on the moisturised side, and the global worst score across erythema, desquamation, dryness, stinging or burning and pruritus was 0.43 on the moisturised side against 0.59 on the adapalene-only side, p = 0.032 (Matsunaga et al., J Dermatolog Treat 2013, PMID 22384983). Note the population: healthy volunteers, not acne patients, and 30 people over 4 weeks. A separate 8 week randomised study in Bangkok assigned 120 Asian patients with mild to moderate acne equally across adapalene gel alone, adapalene plus an active moisturiser, and adapalene plus a placebo moisturiser, and reported less irritation on bioengineering measures in the active moisturiser group without loss of adapalene efficacy (Chularojanamontri et al., J Dermatolog Treat 2016, PMID 26293170).

Wrinkles And Photoaging

The FDA approved indication for both the over the counter 0.1% gel and the prescription 0.3% gel is acne vulgaris in patients 12 years of age and older. Anti-aging is not an approved use, and any product marketed to you on that basis is going beyond the label.

The research is more interesting than the label. An investigator-blinded, parallel-group study in Brazil randomised subjects 1:1 to once daily adapalene 0.3% gel or tretinoin 0.05% cream and assessed them through week 24 on clinical signs of photoaging plus histopathology and digital morphometry. Adapalene 0.3% gel was non-inferior to tretinoin 0.05% cream, with no significant difference on global cutaneous photoaging, periorbital wrinkles, ephelides and melanosis, forehead wrinkles, or actinic keratosis, and a similar safety profile (Bagatin et al., Eur J Dermatol 2018, PMID 30105991). The published abstract does not state the number randomised, so we are not quoting one.

The strength in that study is the important detail. It used adapalene 0.3%, the prescription gel, not the 0.1% gel sold over the counter, and the two are not interchangeable on the evidence. Older mechanistic support for retinoids and collagen exists but comes from animal work: a study in photoaged hairless mice found that retinoids, including both tretinoin and adapalene, produced a wider collagen repair zone than control, while 585 nm and carbon dioxide laser resurfacing did not differ from control, and combining lasers with adapalene added nothing beyond adapalene alone (Lee et al., Aesthetic Plast Surg 2008, PMID 18301943). That is a mouse result and should be read as one.

Pregnancy And What The Animal Data Says

Retinoids and pregnancy is a topic where imprecision does real harm in both directions, so here is exactly what the sources say and where each figure comes from.

The over the counter Drug Facts label routes the question to a clinician: if pregnant or breast-feeding, ask a doctor before use, and stop use and ask a doctor if you become pregnant or are planning to become pregnant while using the product. The prescription adapalene gel 0.3% label states that available data from clinical trials in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. The registration trial itself excluded women who were pregnant, nursing or planning to become pregnant, and required those of childbearing potential to have a negative pregnancy test and to use a highly effective contraceptive method during the trial, which is why human data from it is thin by design.

A safety analysis published as part of the US prescription to over the counter switch calculated a margin of safety of 70 for adapalene 0.1% gel for potential teratogenic effects, using a maximal usage pharmacokinetic trial in adolescents and adults with mainly severe acne together with rat and rabbit embryo-fetal development studies, and reported that a review of pregnancy data found no pregnancy malformations attributable to topical adapalene use. The authors stated their own limits in the same abstract: animal studies do not always predict effects in human development, and the safety data is voluntarily reported and intrinsically incomplete (Weiss et al., J Drugs Dermatol 2021, PMID 34898146).

Reading all of that together: the reassuring findings and the malformation findings come from different routes and different exposure multiples, and none of it replaces the label instruction to ask a doctor. If you are pregnant, breastfeeding, or planning a pregnancy, that conversation with a doctor or pharmacist is the answer, not a web page.

Where Peptides Fit

Retinoids and skin peptides are often discussed as competitors, which misreads both. Adapalene is an approved acne drug with receptor-level activity and a regulatory file behind it. Copper peptides such as GHK-Cu are studied along a different pathway, and the topical GHK-Cu profile sets out what that research does and does not show. Neither page claims a peptide replaces a retinoid, and we have not found a head to head trial of adapalene against a topical peptide to point you at.

The one interaction worth knowing is the label one, not a peptide one: the adapalene labels flag that irritation is more likely when more than one topical acne medication is used at the same time, and the prescription label asks for caution with other potentially irritating topical products, naming medicated or abrasive soaps and cleansers, strongly drying soaps and cosmetics, and products high in alcohol, astringents, spices or lime. Layering decisions belong with whoever knows your skin.

The Short Version